Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, et al.
Leukemia (2015) Vol. 30, Iss. 1, pp. 136-143
Closed Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
Peter Valent, Cem Akin, Karin Hartmann, et al.
Cancer Research (2017) Vol. 77, Iss. 6, pp. 1261-1270
Open Access | Times Cited: 231
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Peter Valent, Cem Akin, Karin Hartmann, et al.
HemaSphere (2021) Vol. 5, Iss. 11, pp. e646-e646
Open Access | Times Cited: 204
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Peter Valent, Cem Akin, Karin Hartmann, et al.
Theranostics (2020) Vol. 10, Iss. 23, pp. 10743-10768
Open Access | Times Cited: 142
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2021) Vol. 96, Iss. 4, pp. 508-525
Open Access | Times Cited: 142
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 140
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti Radia, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2192-2199
Open Access | Times Cited: 103
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2023) Vol. 98, Iss. 7, pp. 1097-1116
Open Access | Times Cited: 57
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2018) Vol. 94, Iss. 3, pp. 363-377
Closed Access | Times Cited: 156
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
Georg Greiner, Bettina Sprinzl, Aleksandra Górska, et al.
Blood (2020) Vol. 137, Iss. 2, pp. 238-247
Open Access | Times Cited: 135
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
Wolfgang R. Sperr, Michael Kundi, Iván Álvarez‐Twöse, et al.
The Lancet Haematology (2019) Vol. 6, Iss. 12, pp. e638-e649
Open Access | Times Cited: 118
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
Daniel J. DeAngelo, Tracy I. George, Andrea Linder, et al.
Leukemia (2017) Vol. 32, Iss. 2, pp. 470-478
Closed Access | Times Cited: 117
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
Andreas Reiter, Tracy I. George, Jason Gotlib
Blood (2020) Vol. 135, Iss. 16, pp. 1365-1376
Open Access | Times Cited: 112
The role of ASXL1 in hematopoiesis and myeloid malignancies
Shuhei Asada, Takeshi Fujino, Susumu Goyama, et al.
Cellular and Molecular Life Sciences (2019) Vol. 76, Iss. 13, pp. 2511-2523
Open Access | Times Cited: 111
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Blood (2017) Vol. 130, Iss. 2, pp. 137-145
Open Access | Times Cited: 104
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Raphaël Itzykson, Pierre Fenaux, David Bowen, et al.
HemaSphere (2018) Vol. 2, Iss. 6
Open Access | Times Cited: 103
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
Mohamad Jawhar, Juliana Schwaab, Iván Álvarez‐Twöse, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 31, pp. 2846-2856
Open Access | Times Cited: 103
Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management
Animesh Pardanani
American Journal of Hematology (2016) Vol. 91, Iss. 11, pp. 1146-1159
Open Access | Times Cited: 102
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Celalettin Üstün, Jason Gotlib, Uday Popat, et al.
Biology of Blood and Marrow Transplantation (2016) Vol. 22, Iss. 8, pp. 1348-1356
Open Access | Times Cited: 90
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
Mohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, et al.
Haematologica (2017) Vol. 102, Iss. 6, pp. 1035-1043
Open Access | Times Cited: 87
MDS overlap disorders and diagnostic boundaries
Tiffany Tanaka, Rafael Bejar
Blood (2019) Vol. 133, Iss. 10, pp. 1086-1095
Open Access | Times Cited: 80
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
Peter Valent, Cem Akin, Karoline V. Gleixner, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 2976-2976
Open Access | Times Cited: 79
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
Peter Valent, Karin Hartmann, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 8, pp. 1999-2012.e6
Open Access | Times Cited: 47
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
Peter Valent, Cem Akin, Wolfgang R. Sperr, et al.
Annual Review of Pathology Mechanisms of Disease (2022) Vol. 18, Iss. 1, pp. 361-386
Open Access | Times Cited: 40
The international consensus classification of eosinophilic disorders and systemic mastocytosis
Sa A. Wang, Attilio Orazi, Jason Gotlib, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1286-1306
Closed Access | Times Cited: 26
The transcriptional program, functional heterogeneity, and clinical targeting of mast cells
Gökhan Cildir, Harshita Pant, Angel F. López, et al.
The Journal of Experimental Medicine (2017) Vol. 214, Iss. 9, pp. 2491-2506
Open Access | Times Cited: 86
Page 1 - Next Page

Scroll to top